U.S. stock night trading volatility: Concerns over governance triggered by the appointment of a new CEO at United, Indaptus's stock price fell 3.40% in night trading

U.S. Stock Night Market Movements Indaptus Therapeutics fell 3.40% in the night market. Based on recent key news: On December 23, Indaptus Therapeutics announced the appointment of David Lazar as co-CEO, which may affect the company's governance structure, drawing market attention and causing the stock price to drop. On December 23, the company submitted a preliminary beneficial ownership statement, listing Avraham Ben-Tzvi as a director and beneficial owner of securities, which may impact investor confidence and lead to stock price fluctuations. On December 23, Benzinga's technical sentiment signal indicated a strong sell, exacerbating the negative trend for the stock and putting pressure on the stock price. The biopharmaceutical industry has recently faced funding pressures. Stocks with High Trading Volume in the Industry Recursion Pharmaceuticals rose 0.45% in the night market, with a trading volume of $761,600, and no significant news recently. The trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Biodexa Pharmaceuticals rose 11.66% in the night market, with a trading volume of $85,500, and no significant news recently. The trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Moderna fell 0.24% in the night market. Based on recent key news: On December 24, Moderna's stock price dropped 5.8% as investors took profits. Previously, the stock price had risen for four consecutive days, reaching its highest level since March. Year-to-date, the stock price has fallen 20%. Source: MarketBeat On December 25, analysts rated Moderna as "underweight," believing its short-term revenue visibility is limited, especially due to its high dependence on the COVID-19 pipeline. Source: MarketBeat On December 26, Moderna faces pipeline complexities and an uncertain regulatory timeline, leading to pressure on the stock price. Analysts are cautious about its long-term prospects. Source: MarketBeat. The mRNA drug market is highly competitive, with significant risks